Posts

Posted on

Silo Pharma, Inc. Expands Scientific Advisory Board with Appointment of Dr. Peter Hendricks of University of Alabama at Birmingham

NEW JERSEY, Dec. 07, 2020 (GLOBE NEWSWIRE) — Silo Pharma, Inc. (OTCQB: SILO) a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that its Board of Directors has named behavioral health expert Dr. Peter Hendricks, Ph.D. to its newly formed Scientific Advisory Board.

Dr. Peter Hendricks is an Associate Professor in the University of Alabama at Birmingham’s (“UAB”) Health and Behavior department where he has led studies and authored a number of published research articles that explore the therapeutic impacts of psychedelic drugs, including psilocybin. UAB is one of the few universities in the world currently investigating the medicinal benefits of psilocybin.

“Peter’s background in drug and behavioral research strongly supplements our team as we pursue and assess new opportunities,” said Eric Weisblum, CEO of Silo Pharma, Inc. “Our Scientific Advisory Board is comprised of some of the most forward-thinking researchers in the industry, and will help to position Silo Pharma, Inc. as a critical player in the pursuit of ground-breaking research and innovation in the field of psychedelic medicine.”

Dr. Hendricks has served as Associate Professor at UAB since 2010. He has focused his research on the interplay between psychedelic-assisted psychotherapy and a host of sociological issues such as criminality, substance abuse, and suicide. His most current area of research focused on the evaluation of the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics.

“Silo Pharma, Inc. will continue to support the research of commercially viable tools and drugs that seek superior outcomes for individuals suffering from emotional and behavioral disorders,” added Weisblum. “The use of psychedelic drugs such as psilocybin, as an alternative therapy, have the potential to be a disruptive force in the treatment of these widespread conditions. I look forward to working with Dr. Hendricks in pursuit of opportunities in this field.”  

Dr. Hendricks earned his Doctor of Philosophy from the University of South Florida in 2006.

About Silo Pharma

Silo Pharma. Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry.  For more information, visit www.silopharma.com.

Safe Harbor and Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.



Investor Relations Contact

:                                      


Hayden IR

Brett Maas
646-536-7331
Email: [email protected]



Posted on

CBD OF DENVER, INC. (CBDD) The Company is working on an Agreement to Supply a Swiss Chain Store with CBD Products

PR Newswire

DENVER, Dec. 7, 2020 /PRNewswire/ — CBD of Denver, Inc. (OTC: CBDD), a full-line CBD and Hemp oil company (“CBDD”) selling Black Pearl CBD hemp products and a producer and distributor of CBD products in Switzerland is in negotiations with a Swiss chain store to supply CBD products.

This week Rockflowr Exchange made their first sale of CBD products to Switzerland’s Spar Retail outlets. Spar has retail grocery outlets throughout Switzerland, signaling what could be the beginning of the mainstreaming of the Rockflowr brand and CBD products in Switzerland. 

The US House passed the MORE Act last week, seeking to decriminalize marijuana and remove it as a Schedule I drug under the Controlled Substances Act. The US Senate must also approve the bill before it can be sent to the president who can sign the bill into law or veto it. Should the bill become law, this will present an opportunity for CBDD to possibly sell Cannabis products in the US and to bring its Rockflowr brand and products to the US. 

“We are very excited about the news that the US House passed the MORE Act to decriminalize and deschedule marijuana and look forward to the federal legalization of marijuana.  When marijuana becomes legal on the federal level, we will look into selling both CBD and marijuana related products in the US.  We are also very pleased with our negotiations with Spar, we have been working on this project for quite some time,” stated CBDD CEO Marcel Gamma.

CBDD is focused on using equity to acquire profitable Swiss assets at attractive valuations to create value for all our shareholders

CBDD offers a superior CBD product that is full spectrum without depending on THC to activate the benefits of cannabidiol. Black Pearl CBD has 0% THC. CBDD just received word that their new ecommerce website will be operational by the end of next week and can be found at www.blackpearlcbd.com.

Information contained herein includes forward-looking statements. These statements relate to future events or future financial performance, involving known and unknown risks and you should not place undue reliance on these statements. Any forward-looking statement reflects our current views with respect to future events. We assume no obligation publicly about update or revise these forward-looking statements for any reason.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/cbd-of-denver-inc-cbdd-the-company-is-working-on-an-agreement-to-supply-a-swiss-chain-store-with-cbd-products-301187033.html

SOURCE CBD of Denver, Inc.

Posted on

Loop Insights Announces Intention To Begin Process Of Uplisting To Major North American Stock Exchanges, Commencing With Application To Uplist On TSX, Followed By Application To Dual-List On NASDAQ

VANCOUVER, British Columbia, Dec. 07, 2020 (GLOBE NEWSWIRE) — Loop Insights Inc. (MTRX:TSXV) (RACMF:OTCQB) (the “Company” or “Loop”), a provider of contactless solutions and artificial intelligence (“AI”) to drive real-time insights, enhanced customer engagement, and automated venue tracing to the brick and mortar space, is pleased to announce the approval by the Board of Directors of the Company’s intended plan (“Uplist Plan”) to begin the process of uplisting to major North American Stock Exchanges.

The Uplist Plan outlines Loop’s proposed plan to apply to have its common shares uplisted to the Toronto Stock Exchange (“TSX”), as a technology company, from the TSX Venture Exchange (“TSXV”). Completion of the Uplist Plan is subject to meeting certain conditions, as well as the approval of the TSX. There is no assurance that the TSX will approve the listing application or that Loop will complete the Uplist Plan as proposed.

Secondly, if the Company is successful in uplisting to the TSX, Loop intends to, as soon as practical, begin the process of filing a Form F-1 Registration Statement with the Securities and Exchange Commission of the United States (the “SEC”), which will enable Loop to apply to be listed on the NASDAQ. In the opinion of the Board, legal counsel, and financial advisors, a NASDAQ listing application would be better served coming from a TSX listed company, as opposed to a direct application from the TSXV. Any such listing application is subject to meeting the stringent conditions of the SEC, as well as, the approval of the NASDAQ. There is no assurance that either the SEC or NASDAQ will approve the Company’s respective applications or that Loop will complete the listing to the NASDAQ as proposed. Loop may elect to not complete the uplist to the TSX or the NASDAQ for a variety of reasons, including, but not limited to, unfavourable market conditions, the additional regulatory and financial burden of being listed on the TSX or the NASDAQ, or other conditions affecting the business or operations of Loop.

UPLIST
PLAN ENACTED IN ANTICIPATION OF COMPANY GROWTH IN 2021

2020 has seen extraordinary growth for the Company in terms of its technology stack, customer acquisitions, Tier-1 partnerships, technology deployments, and most importantly, the growth of the Company’s sales pipeline. Though Loop cannot provide any assurances as to the success stemming from its current and growing sales pipeline, we are of the strong opinion that we will continue to see increased demand in the marketplace for our AI data applications and product services. The digital transformation driven by COVID-19 has accelerated Loop’s products across all industries and channels. As a result, Loop is well-positioned to be a big winner in the global digital transformation opportunity, as we seek to develop the connective tissue that bridges all data worlds together in real-time.

The Company’s main goal from the outset was to be the first publicly-traded, Artificial Intelligence, data play that delivers the ability to connect and to provide real-time data applications across the big three channels; In-Store, E-Commerce, and M-Commerce. The Company has not only accomplished this goal in 2020, it has begun to commercialize and build a strong pipeline of Tier-1 global brands.

Loop Insights CEO Rob Anson stated, “As a result of our immutable relevancy, high demand for Loop’s products, pipeline growth, and ability to easily scale into a global marketplace that is in full press digital transformation, we expect a continued accelerated pace that now warrants an uplist and dual list strategy that will attract institutional investors commensurate with our anticipated profile in 2021 and far beyond.”

This Press Release Is Available On The Loop Insights Verified Forum On AGORACOM For Shareholder Discussion And Management Engagement https://agoracom.com/ir/LoopInsights/forums/discussion

About Loop Insights

Loop Insights Inc. is a Vancouver-based Internet of Things (“IoT”) technology company that delivers transformative artificial intelligence (“AI”) automated marketing, venue tracing, and contactless solutions to the brick-and-mortar space. Its unique IoT device, Fobi, enables data connectivity across online and on-premise platforms to provide real-time, detailed insights and automated, personalized engagement. Its ability to integrate seamlessly into existing infrastructure, and customize campaigns according to each vertical, creates a highly scalable solution for its prospective global clients that span industries. Loop Insights operates in the telecom, casino gaming, sports and entertainment, hospitality, and retail industries, in Canada, the US, the UK, Latin America, Australia, Japan, and Indonesia. Loop’s products and services are backed by Amazon’s Partner Network.

For more information, please contact:

Loop Insights Inc.   LOOP Website: www.loopinsights.ai
Rob Anson, CEO   Facebook: @ LoopInsights
T: +1 877-754-5336 Ext. 4   Twitter: @ LoopInsights
E: [email protected]   LinkedIn: @ LoopInsights


Forward-Looking Statements/Information:
 

This news release contains certain statements which constitute forward-looking statements or information including, but not limited to, Loop’s anticipated decision, plans, and timing related to the potential
uplisting
to the
TSX
and the NASDAQ, and Loop’s ability to meet TSX and/or NASDAQ listing requirements. Such forward-looking statements are subject to numerous risks and uncertainties, some of which are beyond Loop’s control, including the impact of general economic conditions, industry conditions, and competition from other industry participants, stock market volatility, interruptions due to availability of parts, illness or quarantines, or delays in deliveries or new or expanded shutdowns and other economic changes related to the current or future civil unrest in certain regions globally or the COVID-19 pandemic, changes to the regulatory regimes currently applicable to Loop, or which may be applicable to Loop should it complete
an
uplisting
to the
TSX
and/or the NASDAQ (which such
uplisting
is not guaranteed and is wholly within the discretion of Loop to complete), and the ability to access
sufficient capital from internal and external sources. Although Loop believes that the expectations in its forward-looking statements are reasonable, they are based on factors and assumptions concerning future events which may prove to be inaccurate. Those factors and assumptions are based upon currently available information. Such forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated, or implied in the forward-looking statements. As such, readers are cautioned not to place undue reliance on the forward-looking statements, as no assurance can be provided as to future results, levels of activity, or achievements. Furthermore, unanticipated changes to Loop’s capital structure, its inability to affect changes to its capital structure, if necessary, to meet
uplisting
requirements on the TSX and/or the NASDAQ, a significant decline or volatility in Loop’s stock price, any changes to the
TSX
and/or NASDAQ
uplisting
requirements, or a decision by the TSX and/or NASDAQ to not approve Loop’s anticipated application to list could impact Loop’s decision or ability to seek such
uplisting
. Accordingly, the reader should not place undue reliance on forward-looking information. The forward-looking statements contained in this news release are made as of the date of this news release and, except as required by applicable law, Loop does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. The forward-looking statements contained in this document are expressly qualified by this cautionary statement. Trading in the securities of Loop should be considered highly speculative. There can be no assurance that Loop will be able to achieve all or any of its proposed objectives.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange)
accept
responsibility for the adequacy or accuracy of this release. 



Posted on

New Study Demonstrates Clinical Utility of PrismRA® Test in Guiding Therapy Selection for Rheumatoid Arthritis Patients

Nine out of 10 responding rheumatologists stated the test would increase their confidence when making prescribing decisions

WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) — Scipher Medicine, a precision immunology company matching patients with the most effective therapy, today announced findings from a clinical utility study published in Rheumatology International that the PrismRA test can lead to major changes in prescribing behaviors. When test results indicated a likelihood of non-response, up to 89% of providers shifted their proposed therapy from tumor necrosis factor inhibitor (TNFi) to an alternative drug class based on the PrismRA score.

The majority of rheumatoid arthritis (RA) patients prescribed the world’s largest selling drug class, TNFi, do not adequately respond to treatment. PrismRA is a first-of-its-kind blood test that accurately predicts patients who will not have an adequate response to TNFi therapy so alternative effective therapy can be prescribed from day one, without first cycling through multiple TNFi drugs.

“The results of this study clearly show that rheumatologists would change their medical management of RA patients if they had access to a predictive biomarker test like PrismRA,” said James Mossell, Doctor of Osteopathic Medicine, Fellow of the American College of Rheumatology and an author of the study. “Rheumatologists are eager to use precision medicine in complex autoimmune diseases such as RA and find high value in eliminating therapies that will likely fail in certain patients before selecting a more optimal targeted therapy.”

The study surveyed 248 rheumatologists as to the clinical utility of a TNFi non-responder biomarker. A vast majority found the test easy to interpret and clinically useful, selection of TNFi therapy declined by 81% (from 79.8% to 15.3%) and 86% (from 79.8% to 11.3%) respectively when presented with a test result indicating a high or very high signal of non-response.

“The clinical breakthrough enabled by PrismRA means more patients will be prescribed effective therapy sooner resulting in significantly improved health outcomes,” said Alif Saleh, CEO of Scipher Medicine. “We are pleased this study demonstrates the support of PrismRA by the rheumatology community.”

About Scipher Medicine

®

Scipher Medicine, a precision immunology company, holds the fundamental belief that patients deserve simple answers to treatment options based on scientifically backed data. Leveraging our proprietary Network Medicine platform and artificial intelligence, we commercialize blood tests revealing a persons’ unique molecular disease signature and match such signature to the most effective therapy, ensuring optimal treatment from day one. The unprecedented amount of patient molecular data generated from our tests further drives the discovery and development of novel and more effective therapeutics. We partner with payers, providers, and pharma along the health care value chain to bring precision medicine to autoimmune diseases. Visit www.sciphermedicine.com and follow Scipher on Twitter, Facebook, and LinkedIn.

About PrismRA

®

PrismRA, a molecular signature test, is a revolutionary advancement bringing precision medicine to the treatment of rheumatoid arthritis, which affects 20 million patients globally. From a routine blood draw, the PrismRA test analyzes an individual’s molecular signature, helping identify who is unlikely to adequately respond to TNFi therapy, the world’s largest selling drug class, so non-responders can be prescribed alternative effective therapy. Providers now have objective data to guide therapeutic decision-making and give patients the best chance of achieving treatment targets and improving clinical outcomes. For more information, please visit www.PrismRA.com

Media Contact:
Alexander Petti
[email protected]
201-978-4882

Scipher Medicine company contact:
Andrea Moore
[email protected]
801.209.1175

Photos accompanying this release are available at 
https://www.globenewswire.com/NewsRoom/AttachmentNg/63fce27f-c5e3-421b-a9c6-e57d9e2ffa99
https://www.globenewswire.com/NewsRoom/AttachmentNg/3a651586-0fb6-433c-af6a-bb41baeb2b0c



Posted on

Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast Cancer

Guardant Health Presents Data at San Antonio Breast Cancer Symposium Demonstrating Utility of GuardantINFORM™ Real-World Platform in Metastatic Breast Cancer

Platform Uncovers Key Clinical-Genomic Insights in Patients Treated with Endocrine Therapy and CDK4/6 Inhibitors for Use in Precision Oncology Drug Development

REDWOOD CITY, Calif.–(BUSINESS WIRE)–
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, shares new data at the 2020 Virtual San Antonio Breast Cancer Symposium (SABCS) showing how its GuardantINFORM™ real-world clinical-genomic platform can be used to gain deeper insights into patients’ treatments and associated response to support the development of more effective therapies for biomarker-defined cancers. The data presented highlight treatment resistance in estrogen receptor positive (ER-positive), HER-2 negative metastatic breast cancer patients.

“While we’ve seen improved outcomes for patients with ER-positive metastatic breast cancer, many eventually develop ESR1 resistance after undergoing endocrine therapy; and new data from patients treated with CDK4/6 inhibitors suggest that clinical outcomes are impacted by a patient’s molecular subtype,” said Helmy Eltoukhy, Guardant Health CEO. “The results presented during SABCS demonstrate the power of our GuardantINFORM platform to deliver real-world clinical-genomic insights to help guide more precise oncology treatments and accelerate drug development efforts for these difficult to treat breast cancers.”

The abstracts, now online, show how this robust platform helps characterize molecular tumor evolution and treatment resistance mechanisms throughout each patient’s treatment journey.

  • Abstract PS18-15: “Real-world clinical-genomic data identifies the ESR1 clonal and subclonal circulating tumor DNA (ctDNA) landscape and provides insight into clinical outcomes” shows how the data from our Guardant360 liquid biopsy dataset demonstrate the heterogeneity of ESR1 mutations associated with endocrine therapy treatment.
  • Abstract PS18-28: “Genomic heterogeneity and associated clinical outcomes of breast cancers treated with CDK4/6 inhibitors: Insights from real-world clinical genomic data” suggests new potential mechanisms of acquired resistance.
  • Abstract OT-07-01:“Guardant360® related clinical outcomes in patients who share medical records-breast cancer (GRECO-B)” shows how Guardant Health takes a novel patient-centric approach to enrolling Guardant360 breast cancer patients into this siteless, prospective, observational health outcomes study to create a more comprehensive view of patients’ clinical journey.

The GuardantINFORM platform is an in silico platform that combines de-identified longitudinal clinical information and genomic data collected from our Guardant360 liquid biopsy test. With data from over 135,000 patients, this real-world clinical-genomic dataset of advanced cancer patients is one of the largest in oncology. Notable applications include targeted drug development, clinical trial optimization, and post-marketing studies.

About Guardant Health

Guardant Health is a leading precision oncology company focused on helping conquer cancer globally through use of its proprietary blood tests, vast data sets and advanced analytics. The Guardant Health Oncology Platform leverages capabilities to drive commercial adoption, improve patient clinical outcomes and lower healthcare costs across all stages of the cancer care continuum. Guardant Health has launched liquid biopsy-based Guardant360®, Guardant360 CDx, and GuardantOMNI® tests for advanced stage cancer patients. These tests fuel development of its LUNAR program, which aims to address the needs of early stage cancer patients with neoadjuvant and adjuvant treatment selection, cancer survivors with surveillance, asymptomatic individuals eligible for cancer screening and individuals at a higher risk for developing cancer with early detection.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential benefits and advantages of the GuardantINFORM platform, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. Such risks and uncertainties include those discussed under the caption “Risk Factors” in Guardant Health’s Annual Report on Form 10-K for the year ended December 31, 2019, its Quarterly Report on Form 10-Q for the period ended March 31, 2020, and in its other reports filed with the Securities and Exchange Commission. These forward-looking statements are based on current expectations, forecasts, assumptions and information available to Guardant Health as of the date hereof, and actual outcomes and results could differ materially from these statements due to a number of factors, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release. Investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Guardant Health.

Source: Guardant Health, Inc.

Investor Contact:

Carrie Mendivil

[email protected]

Media Contact:

Anna Czene

[email protected]

Courtney Carroll

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Biotechnology Oncology Health Medical Devices Data Management Hospitals Technology Genetics

MEDIA:

Logo
Logo
Posted on

Saba Capital Reaches Agreement with Royce Global Value Trust, Inc. to Tender 50% of its Shares

Saba Capital Reaches Agreement with Royce Global Value Trust, Inc. to Tender 50% of its Shares

NEW YORK–(BUSINESS WIRE)–
Saba Capital Management, L.P. and certain associated parties (collectively “Saba”) today announced that it has reached an agreement with Royce Global Value Trust, Inc. (NYSE: RGT) (the “Fund”).

Under the terms of the agreement, the Fund shall amend the terms of its Tender Offer Statement on Schedule TO filed on October 28, 2020 to reflect a revised tender offer to purchase for cash up to 50% of its outstanding common shares at a price per Share equal to 100% of the Fund’s net asset value per Share with an expiration date of 11:59 p.m., New York City time on December 21, 2020 (the “Revised Tender Offer”). The Fund will repurchase shares tendered and accepted in the Revised Tender Offer in exchange for cash.

About Saba Capital

Saba Capital Management, L.P. is an Investment Adviser based in New York. Launched in 2009, Saba currently manages assets across three core strategies: Credit Relative Value, Tail Hedge and Closed-End Funds.

Investors

Leah Jordan

Investor Relations

[email protected]

Media

Gasthalter & Co.

Jonathan Gasthalter/Amanda Klein

212-257-4170

KEYWORDS: New York United States North America

INDUSTRY KEYWORDS: Consulting Banking Professional Services Finance

MEDIA:

Posted on

Wyloo Metals to purchase cornerstone position in Noront Resources from Resource Capital Fund V L.P.

PERTH, Australia, Dec. 07, 2020 (GLOBE NEWSWIRE) — Wyloo Metals Pty Ltd. (Wyloo Metals) has entered into a definitive agreement to become a cornerstone investor in Noront Resources Ltd. (Noront) through the acquisition of all beneficial interests in Noront controlled by Resource Capital Fund V L.P. and its affiliates (RCF).

The deal is Wyloo Metals’ second Canadian investment, and follows several similar strategic investments aimed at supporting the discovery and development of critical commodities required to decarbonise the global economy.

Under the terms of the deal, Wyloo Metals will acquire the following instruments held by RCF:

  • 94,553,126 Noront common shares and warrants to acquire 1,774,664 Noront common shares;
  • US$15,000,000 convertible loan maturing September 30, 2021; and
  • a 1.0% net smelter return royalty over the Eagle’s Nest deposit.

Noront is a Canadian listed mining company with several assets, including the high-grade Eagle’s Nest nickel project in the Ring of Fire, an emerging multi-metals region located in the James Bay Lowlands of Northern Ontario.

Eagle’s Nest is the largest high-grade nickel discovery in Canada since Voisey’s Bay and is anticipated to have an initial mine life of 11 years, with the potential for an additional nine years. This excludes the development of the adjacent chromite resources, which presents a further development opportunity.

Once developed, the Ring of Fire has the potential to generate significant business and employment benefits for Ontario’s north-western region. Analysis by the Ontario Chamber of Commerce1 shows that within the first 10 years of its development, the Ring of Fire has the potential to contribute:

  • up to C$9.4 billion in Gross Domestic Product (GDP);
  • up to 5,500 jobs annually; and
  • nearly C$2.0 billion in government revenue, divided between the federal, provincial and municipal governments and First Nations communities.

In line with the potential economic importance of the Ring of Fire, the Province of Ontario has indicated it will commit up to C$1.0 billion towards infrastructure development subject to Federal Government support, to ensure the necessary investment to access the region will proceed. In March 2020, the Government of Ontario, Marten Falls First Nation and Webequie First Nation announced a new partnership to advance the planning and development of a proposed Northern Road Link that would provide reliable, all-season road access to potential mine sites and connect First Nation communities to Ontario’s provincial highway network.

Head of Wyloo Metals, Luca Giacovazzi, said the partnership with Noront presents a unique opportunity to join forces with a proven management team in the development of the Eagle’s Nest deposit and the continued exploration of the world-class Ring of Fire region.

“This investment reflects a long-term and collaborative strategy to support the discovery and development of the next generation of mines required to meet the growing demand of critical materials needed to power the decarbonisation of the global economy,” Mr Giacovazzi said.

“At the centre of our approach is a belief that by building strong businesses, we can create economic opportunities that enable communities to thrive. We look forward to forming a long-term working relationship with the Noront team and key stakeholders as we advance the assets over the coming years.

Noront President and CEO Alan Coutts said: “We’re extremely pleased that Wyloo Metals has chosen to make a cornerstone investment in Noront. They are known for making long-term, strategic investments in companies that mine responsibly, and that is a philosophy that aligns very well with the approach we are taking as we develop the Ring of Fire in an environmentally responsible manner in collaboration with our First Nation partners.”

Under the terms of its agreements with RCF, Wyloo Metals will purchase the 94,553,126 Noront common shares for an aggregate purchase price of US$11.5 million (C$14.8 million, or C$0.16 per share) and will purchase the convertible loan for US$15.0 million (which is the principal amount of the loan). The Noront common shares to be acquired represent approximately 22.65% of the 417,512,534 currently outstanding Noront common shares. Based on the current conversion price of the loan, Wyloo Metals would acquire 96,600,000 Noront common shares upon full conversion of the loan and would, if the warrants it is to acquire were also exercised, result in Wyloo Metals holding 192,927,790 Noront common shares, representing approximately 37.40% of the Noront common shares on a partially diluted basis.

As part of the proposed transaction, Noront will grant to Wyloo Metals investor rights consistent with the rights currently held by RCF (including pre-emptive rights and rights to two board nominees).

This acquisition by Wyloo Metals is for investment purposes. Wyloo Metals does not have any current plans or intentions to buy or sell further Noront shares (other than potentially exercising its loan conversion or warrant exercise rights), to solicit proxies or to otherwise participate in any significant transaction involving Noront.

Wyloo Metals will review its investment on a continuing basis. Depending on various factors, it may in the future purchase or sell securities or engage in other activities relating to Noront.

Closing of the transactions is subject to customary closing conditions, including approval of the TSX Venture Exchange.

Wyloo Metals will be filing an early warning report under Noront’s profile on SEDAR, and copies of the report may be obtained at sedar.com.

The acquisitions of these securities from RCF is to be made in reliance upon the “private agreement” exemption from the formal take-over bid requirements of applicable Canadian securities legislation. The per share price to be paid by Wyloo Metals is less than the market price of the Noront common shares as determined in the manner prescribed by applicable Canadian securities legislation.

ABOUT NORONT AND THE RING OF FIRE

Noront is a Canadian-based miner principally focused on the responsible development of the high-grade Eagle’s Nest nickel, copper, platinum and palladium deposit and the world class chromite deposits including Blackbird, Black Thor and Big Daddy, all of which are located in the Ring of Fire region of Northern Ontario.

Development of the Ring of Fire region will require the permitting and construction of an approximately 300-kilometre all-season road, utilises a north-south corridor from the Ring of Fire to the provincial highway and rail systems. More recently the First Nations communities with traditional land use in the area have taken leadership of the environmental assessment process as the proponents for road, working closely with the Government of Ontario to open up access to the Ring of Fire.

ABOUT WYLOO METALS AND TATTARANG

Wyloo Metals is the metals and mining subsidiary of Tattarang, one of Australia’s largest private investment groups.

Led by a multidisciplinary team of geologists, engineers and financial professionals, Wyloo Metals manages a diverse portfolio of exploration and development projects and cornerstone interests in a number of public and private companies. Wyloo Metals seeks to work closely with all stakeholders to accelerate projects through the development cycle while meeting the highest international environmental, social and governance standards.

MEDIA CONTACT:

Andrew Bennett
M             +61 427 782 503
P             +61 8 6460 4949
E             [email protected]

AURORA SPOKESPERSON:

David Ellis
M             416 704 0937
P             416 907 2126
E             [email protected]

____________________

1 Ontario Chamber of Commerce, Beneath the Surface Uncovering the Economic Potential of Ontario’s Ring of Fire, occ.ca/wp-content/uploads/Beneath_the_Surface_web-1.pdf.



Posted on

Noront Welcomes New Partner Wyloo Metals

TORONTO, Dec. 07, 2020 (GLOBE NEWSWIRE) — Noront Resources Ltd. (“Noront”) (TSX Venture: NOT) is pleased to welcome its new cornerstone security holder Wyloo Metals Pty Ltd. (“Wyloo Metals”) which has entered into an agreement to acquire the beneficial equity and debt interests previously held by Resource Capital Fund V L.P.

Wyloo Metals is the mining division of Tattarang, one of Australia’s largest private investment groups. A long-term and collaborative investor supporting the discovery and development of the next generation of mines, Wyloo Metals is led by a multidisciplinary team of geologists, engineers and financial professionals. The company works closely with all stakeholders to accelerate projects through the development cycle while meeting the highest international environmental, social and governance standards.

“We are delighted that Wyloo Metals has chosen to acquire a cornerstone interest in Noront,” said Noront President and CEO Alan Coutts. “It’s exciting to partner with a company whose values parallel our own company principles. Wyloo makes long-term strategic investments in companies that mine responsibly, and that’s a philosophy that aligns very well with the approach Noront is taking as we develop the Ring of Fire in an environmentally responsible manner in collaboration with our First Nation partners.”

Head of Wyloo Metals, Luca Giacovazzi, said the partnership with Noront presents a unique opportunity to join forces with a proven management team in the development of the Eagle’s Nest deposit and the continued exploration of the world-class Ring of Fire region. “This investment reflects a long-term and collaborative strategy to support the discovery and development of the next generation of mines required to meet the growing demand of critical materials needed to power the decarbonisation of the global economy,” Mr. Giacovazzi said.


Financial Details


Pursuant to a purchase agreement between Wyloo Metals and Resource Capital Fund V and Resource Capital Annex Fund V (collectively, “RCF”), the parties have entered into an agreement to purchase all of RCF’s interests in Noront; this includes its equity interest, representing approximately 22.5% of Noront’s issued and outstanding common shares, a US$15 million convertible debenture and its 1.0% NSR on Noront’s Eagle’s Nest deposit.

As a result of this third-party transaction, Wyloo Metals will become a control person of Noront and will have the right to nominate two members to Noront’s Board of Directors, one of which must be independent of Wyloo Metals.


About Wyloo Metals


Wyloo Metals is the metals and mining subsidiary of Tattarang, one of Australia’s largest private investment groups. Led by a multidisciplinary team of geologists, engineers and financial professionals, Wyloo Metals manages a diverse portfolio of exploration and development projects and cornerstone interests in a number of public and private companies. See more at: www.wyloometals.com


About Noront


Noront is focused on development of its high-grade Eagle’s Nest nickel, copper, platinum and palladium deposit and the world class chromite deposits including Blackbird, Black Thor, and Big Daddy, all of which are located in the James Bay Lowlands of Ontario in an emerging metals camp known as the Ring of Fire. www.norontresources.com

For
more information
please contact:

Janice Mandel
[email protected]
(647) 300-3853



Posted on

Freshpet, Inc. to Participate in Virtual Fireside Chat Hosted by Baird

SECAUCUS, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) — Freshpet, Inc. (“Freshpet” or the “Company”) (NASDAQ:FRPT) today announced that members of the executive management team will participate in a virtual fireside chat hosted by Baird after the market close on December 10, 2020.

The webcast and accompanying presentation will be made available on Thursday, December 10 at 6:00 p.m. ET and can be accessed over the Internet and hosted on the “Investors” section of the Company’s website at www.freshpet.com.

About Freshpet

Freshpet’s mission is to improve the lives of dogs and cats through the power of fresh, real food. Freshpet foods are blends of fresh meats, vegetables and fruits farmed locally and made at our Kitchens in Bethlehem PA.  We thoughtfully prepare our foods using natural ingredients, cooking them in small batches at lower temperatures to preserve the natural goodness of the ingredients. Freshpet foods and treats are kept refrigerated from the moment they are made until they arrive at Freshpet Fridges in your local market.

Our foods are available in select mass, grocery (including online), natural food, club, and pet specialty retailers across the United States, Canada and Europe. From the care we take to source our ingredients and make our food, to the moment it reaches your home, our integrity, transparency and social responsibility are the way we like to run our business. To learn more, visit www.freshpet.com.

Connect with Freshpet:

https://www.facebook.com/Freshpet 

https://twitter.com/Freshpet 

http://instagram.com/Freshpet 

http://pinterest.com/Freshpet 

https://en.wikipedia.org/wiki/Freshpet 

https://www.youtube.com/user/freshpet400 

CONTACT
ICR
Jeff Sonnek
646-277-1263
[email protected]



Posted on

Aeterna Zentaris Announces European Licensing Agreement with Consilient Health Ltd. for Commercialization of Macimorelin

CHARLESTON, S.C., Dec. 07, 2020 (GLOBE NEWSWIRE) — Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS), through its wholly-owned subsidiary, (“Aeterna” or the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive licensing agreement (the “Agreement”) with Consilient Health, Ltd. (“CH” or “Consilient Health”), a privately owned pharmaceutical company focused on commercializing medicines in Europe and Middle East, for the commercialization in Europe and the United Kingdom of macimorelin, Aeterna’s orally available ghrelin agonist, in any diagnostic application, including the diagnosis of patients with adult growth hormone deficiency (“AGHD”) and, subject to receipt of regulatory approval, childhood-onset growth hormone deficiency (“CGHD”).

Under the terms of the Agreement, CH will be responsible for obtaining pricing and reimbursement approval in the European economic area and the United Kingdom, as well as bearing the regulatory cost for the label extension for pediatric use pending successful outcome of the upcoming safety and efficacy study, AEZS-130-P02 (“Study P02”), evaluating macimorelin for the diagnosis of CGHD. This pivotal Phase 3 Study P02 is expected to be initiated in Q1 of 2021. Aeterna and Consilient Health have also entered into a separate commercial supply agreement under which Consilient Health will purchase macimorelin from Aeterna and Aeterna will be responsible for supply and product quality. Aeterna will continue to maintain control of its patents covering macimorelin in Europe and the United Kingdom.

As agreed, Consilient Health will make an up-front payment to Aeterna of Euro 1 million and will pay to Aeterna royalties on net sales of macimorelin ranging from 10% to 20% depending on the level of net sales achieved by Consilient Health in the particular year. Aeterna will also be eligible to receive milestone payments associated with the achievement of pricing and reimbursement approvals in certain countries in Europe and in the United Kingdom, upon approval of macimorelin in CGHD, and on the attainment by Consilient Health of other sales based events.

“This license agreement represents another significant milestone for the Company as we continue to secure and bolster our portfolio of marketing partners for macimorelin in key markets. As a synergistic partner of choice with insight and commercialization capabilities, we believe that Consilient Health brings noteworthy expertise that is the right fit for Aeterna. We are grateful for their partnership and look forward to leveraging their experience in driving innovative marketing to our international distribution network for macimorelin,” commented Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris.

Commenting on the agreement, Ahmed Al-Derzi, Consilient Health’s CEO stated, “We are delighted to build this partnership with Aeterna Zentaris for macimorelin. Not only does the brand further strengthen our growing offering to endocrinology specialists and their patients but it also strengthens CH’s position across Europe. Macimorelin is an exciting innovation in the field of growth hormone deficiency.”

In addition to advancing its pediatric program, Aeterna is actively pursuing its business development activities with the goal of securing marketing partners for macimorelin for the diagnosis of growth hormone deficiency in additional markets where the Company does not already have partnership agreements.

The Agreement will be filed on SEDAR at www.sedar.com. The foregoing description of the terms of the Agreement does not purport to be complete and is qualified in its entirety by reference to the Agreement.

About Consilient Health

Consilient Health is a pharmaceutical company with a rich heritage of commercializing products in areas such as women’s health, urology and endocrinology.

In all of Consilient Health’s planning, the patient is very much at the center. Considering the needs of both the healthcare professional and the payer, as well as those of the patient is key to its commercial success.

Established in 2005, Consilient Health’s success has been built on cultivating strong partnerships with pharma companies and on ensuring access and then marketing prescription healthcare products across Europe and the Middle East.

About Macimorelin

Macimorelin, a ghrelin agonist, is an orally active small molecule that stimulates the secretion of growth hormone from the pituitary gland. Stimulated growth hormone levels are measured in blood samples after oral administration of macimorelin for the assessment of GHD.

In December 2017, the United States Food and Drug Administration (“FDA”) granted Aeterna Zentaris marketing approval for macimorelin to be used in the diagnosis of patients with adult growth hormone deficiency. Macrilen™ has been granted Orphan Drug designation by the FDA for diagnosis of AGHD. In January 2019, the European Commission granted marketing authorization for macimorelin to Aeterna Zentaris for diagnosis of growth hormone deficiency in adults. In March 2017, the Pediatric Committee of the EMA agreed to the Company’s PIP for macimorelin, a prerequisite for filing a marketing authorization application for any new medicinal product in Europe.

About Aeterna Zentaris Inc.

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company’s lead product, macimorelin, is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macimorelin is currently marketed in the United States under the tradename Macrilen™ through a license agreement with Novo Nordisk where Aeterna Zentaris receives royalties on sales. According to a commercialization and supply agreement, MegaPharm Ltd. will seek regulatory approval and then commercialize macimorelin in Israel and the Palestinian Authority. Additionally, upon receipt of pricing and reimbursement approvals, Aeterna expects that macimorelin will be marketed in Europe and the United Kingdom through a recently established license agreement with Consilient Health Ltd and Aeterna Zentaris will receive royalties on sales and other potential payments.

Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD), an area of significant unmet need.

The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value. For more information, please visit www.zentaris.com and connect with the Company on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains forward-looking statements (as defined by applicable securities legislation) made pursuant to the safe-harbor provision of the U.S. Securities Litigation Reform Act of 1995, which reflect our current expectations regarding future events. Forward-looking statements include those relating to the Company obtaining approval of macimorelin for CGHD, the Company’s ability to secure marketing partners for macimorelin in other key markets, the timing of the commencement of the CGHD Study P02, and may include, but are not limited to statements preceded by, followed by, or that include the words “will,” “expects,” “believes,” “intends,” “would,” “could,” “may,” “anticipates,” and similar terms that relate to future events, performance, or our results. Forward-looking statements involve known and unknown risks and uncertainties, including those discussed in this press release and in our Annual Report on Form 20-F, under the caption “Key Information – Risk Factors” filed with the relevant Canadian securities regulatory authorities in lieu of an annual information form and with the U.S. Securities and Exchange Commission. Known and unknown risks and uncertainties could cause our actual results to differ materially from those in forward-looking statements. Such risks and uncertainties include, among others, our ability to raise capital and obtain financing to continue our currently planned operations, our ability to continue to list our Common Shares on the NASDAQ, our now heavy dependence on the success of Macrilen™ (macimorelin) and related out-licensing arrangements and the continued availability of funds and resources to successfully commercialize the product, including our heavy reliance on the success of the License Agreement with Novo Nordisk, the global instability due to the global pandemic of COVID-19, and its unknown potential effect on our planned operations, including studies, our ability to enter into out-licensing, development, manufacturing, marketing and distribution agreements with other pharmaceutical companies and keep such agreements in effect, our reliance on third parties for the manufacturing and commercialization of Macrilen™ (macimorelin), potential disputes with third parties, leading to delays in or termination of the manufacturing, development, out-licensing or commercialization of our product candidates, or resulting in significant litigation or arbitration, uncertainties related to the regulatory process, unforeseen global instability, including the instability due to the global pandemic of the novel coronavirus, our ability to efficiently commercialize or out-license Macrilen™ (macimorelin), our reliance on the success of the pediatric clinical trial in the European Union (“E.U.”) and U.S. for Macrilen™ (macimorelin), the degree of market acceptance of Macrilen™ (macimorelin), our ability to obtain necessary approvals from the relevant regulatory authorities to enable us to use the desired brand names for our product, our ability to successfully negotiate pricing and reimbursement in key markets in the E.U. for Macrilen™ (macimorelin), any evaluation of potential strategic alternatives to maximize potential future growth and shareholder value may not result in any such alternative being pursued, and even if pursued, may not result in the anticipated benefits, our ability to take advantage of business opportunities in the pharmaceutical industry, our ability to protect our intellectual property, and the potential of liability arising from shareholder lawsuits and general changes in economic conditions. Investors should consult our quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties. Given these uncertainties and risk factors, readers are cautioned not to place undue reliance on these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, unless required to do so by a governmental authority or applicable law.

Investor Contact:

Jenene Thomas
JTC Team
T (US): +1 (833) 475-8247
E: [email protected]